Cheil Bio Co

Cheil Bio Co OCF/Debt

Delisted·Feb 25, 2026

The Operating Cash Flow to Debt Ratio of Cheil Bio Co (052670.KQ) as of Nov 17, 2026 is -2,059.96 %. In the previous year, Operating Cash Flow to Debt Ratio was 11,563.32 % — a change of -117.81% (lower).

OCF/Debt

-2,059.96 %

YoY

-117.81%

Last updated:

Operating Cash Flow to Debt Ratio of Cheil Bio Co is 2023 -2,059.96 % . Operating Cash Flow to Debt Ratio of Cheil Bio Co was 2022 11,563.32 % . It decreases by -117.81% lower compared to the previous year.

The Cheil Bio Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2014
22.07 KRW
Jan 1, 2015
-4.84 KRW
Jan 1, 2016
204.85 KRW
Jan 1, 2017
604.35 KRW
Jan 1, 2019
9,314.81 KRW
Jan 1, 2020
-47,429.08 KRW
Jan 1, 2022
11,563.32 KRW
Jan 1, 2023
-2,059.96 KRW
The Cheil Bio Co OCF/Debt history
YEAROCF/DebtYoY
-2,059.96 %-117.81%
11,563.32 %-124.38%
-47,429.08 %-609.18%
9,314.81 %+1,441.30%
604.35 %+195.02%
204.85 %-4,334.46%
-4.84 %-121.92%
22.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cheil Bio Co Stock analysis

What does Cheil Bio Co do? Cheil Bio Co., Ltd. generates revenue through the production and sale of veterinary products for pigs, cattle, chickens, cows, and aquatic animals. The company offers antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, and diagnostic kits including ELISA test kits, virus test kits, and DNA kits. These products are primarily sold to the domestic market, targeting livestock farmers and veterinary clinics. The firm also provides feed additives as part of its product portfolio. The company's product range includes specialized solutions for cattle, pigs, chickens, pets, and other animals, with a focus on health management and disease prevention. Veterinary clinics and livestock farms form the core customer segments, purchasing antibiotics, vaccines, and diagnostic tools to maintain animal health. The domestic market remains the primary sales channel, with no mention of international distribution. Cheil Bio's offerings are designed to address common health challenges in livestock, such as infections and parasitic infestations, through both preventive and therapeutic products. The inclusion of diagnostic kits like ELISA and DNA tests supports advanced veterinary care, enhancing the company's value proposition for professional animal health providers. Cheil Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cheil Bio Co stock

Operating Cash Flow to Debt Ratio of Cheil Bio Co is -2,059.96 % in 2023.

Operating Cash Flow to Debt Ratio of Cheil Bio Co changed from 11,563.32 % to -2,059.96 %, representing a -117.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Cheil Bio Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Cheil Bio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cheil Bio Co

All Key Metrics — Cheil Bio Co